Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vega Therapeutics
South San Francisco, California, United Statesvega-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vega Therapeutics is conducting a Phase 1 clinical trial for VGA039, a first-in-class antibody therapy for von Willebrand disease. The FDA has granted orphan drug designation for VGA039. The ongoing Phase 1 study (NCT05776069) is evaluating safety, tolerability, pharmacokinetic, and pharmacodynamic profiles in healthy volunteers and VWD patients across sites in the EU and US.
- Therapeutic areas
- Hematology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
Beyond the preview
Go deeper on Vega Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vega Therapeutics.